Endometrial Cancer Treatment Market Analysis, Growth rate and Future Analysis
The global endometrial cancer treatment market is expected to witness growth due to unmet need of treatment, technological advancement in cancer therapeutics and diagnostic test, rising prevalence of cancer, and sedentary lifestyle of women. In addition, increasing awareness about the uterine diseases and the available therapies and increasing healthcare expenditure is also driving the growth of global endometrial cancer treatment market.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/report-sample
The pharmaceutical companies are actively involved in the endometrial cancer research and development. AEterna Zentaris, Inc., is developing Zoptrex (zoptarelin doxorubicin), a Phase III clinical trial drug candidate for the treatment of endometrial cancer. In October 2016, the company entered into licensing agreement with Specialized Therapeutics Asia, a biopharmaceutical company, for the marketing of zoptarelin doxorubicin in Australia and New Zealand.
Certain factors such as high treatment cost, low success rate of clinical trials, side effects of the treatment, high research and development expenditure, and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.
Explore Full Report at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market
Some of the key players operating in the global market are Bristol-Myers Squibb Company, Merck & Co., Inc., Ariad Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.
Healthcare Electronic Data Interchange Market Analysis, Size, Trends and Growth, 2023
Healthcare electronic data interchange (EDI) facilitates the exchange of healthcare data which is processed using computer software in a standardized format. Healthcare industry processes a large number of documents such as medical records of patients, healthcare claims, and reimbursement records. Healthcare EDI helps in the exchange of this information among healthcare institutions, healthcare professionals, and patients. The use of healthcare EDI increases accuracy, improves productivity, helps in faster identification of errors, consumes less time, secures exchange of information and leads to ease of work for the healthcare providers, healthcare payers, and pharmacies. Healthcare EDI finds application in insurance and reimbursement data management, clinical trials and regulatory data management, and medical and dental patient database management. They key players such as Dell Technologies Inc. are prompting the growth of the global healthcare EDI market. In February 2017, Dell Technologies Inc. quickened the digital transformation in healthcare EDI market with the introduction of cloud integration solution for healthcare EDI.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/healthcare-edi-market/report-sample
Global healthcare EDI market is expected to grow significantly during the forecast period. Some of the major factors driving growth of the market include expanding base of patient due to the increasing prevalence of chronic diseases, rising need to curtail healthcare costs, and government support for healthcare EDI. According to the World Health Organization (WHO), chronic disease is the leading cause of mortality globally, comprising 60% of all deaths. Also, approximately 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths. Of these deaths, an approximate of 7.4 million deaths were due to coronary heart disease and 6.7 million were due to stroke. WHO also reported that globally 8.8 million people died from cancer which is 1 in 6 of all global deaths in 2015. With the rise in these chronic diseases, the volume of patient is also increasing. Moreover, these large number of deaths also prompts the end users to avail healthcare EDI products for different reimbursements claims.
The key trend witnessed in the global healthcare EDI market is increasing number of research and development activities. With the rising prevalence of adoption of advanced technology in the healthcare market, the key players are investing more on the research and development on healthcare EDI, for the growth of the global healthcare EDI market. Additionally, increasing use of EDI in healthcare manufacturing and distribution industry and growing focus on integration platform as a service (IPAAS) are major trends observed in the global healthcare EDI market. The increase in outsourcing of EDI services and introduction of ICD-11 guidelines are creating ample opportunities for the growth of the global healthcare EDI market.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=healthcare-edi-market
Some of the key players in the global healthcare EDI market are GE Healthcare, Cognizant Technology Corporation, Cerner Corporation, Axway Software SA, Dell Technologies Inc., Synnex Corporation, McKesson Corporation, Allscripts Healthcare Solutions Inc., SSI Group, LLC, Comarch SA, Optum Inc., and Quality Systems Inc.
Neisseria Gonorrhoeae Infections Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaboration
Neisseria gonorrhoeae infections is a sexually transmitted disease that is caused by Neisseria gonorrhoeae bacterium which cause infections in throat, rectum, and genitals. In men, the observed symptoms of gonorrhoeae infections are burning sensation during urination, painful and swollen testicles, and white, green or yellow discharge from the penis. In women, the observed symptoms of gonorrhoeae are vaginal bleeding during periods, increased vaginal discharged, and burning sensation during urination. The unprotected vaginal, oral or anal sex are the risk factors for gonorrhoeae infections. Entasis Therapeutics, Inc. is in the process of developing ETX0914 as a bacterial type II topoisomerases inhibitor, for the treatment of gonorrhoeae infections. Therapyx, Inc. is also in the process of developing IL12 NanoCap for the treatment of gonorrhoeae infection. Some of the companies having the pipeline of neisseria gonorrhoeae infections include Therapyx, Inc., Entasis Therapeutics, Inc., and others.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/neisseria-gonorrhoeae-infections-therapeutics-pipeline-analysis/report-sample
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Explore Report at: https://www.psmarketresearch.com/market-analysis/neisseria-gonorrhoeae-infections-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Melasma Therapeutics Pipeline Review 2018
Melasma, also known as chlosma, is characterized by localized, chronic acquired hypermelanosis of the skin that occur due to melanogenesis dysfunction. It is characterized by the appearances of brown macules distributed symmetrically on the sun-exposed area of the body. It generally occurs due to more use of dermatological care products. The disease affects the quality of life of patient, due to frequent facial involvement. Some of the risk factor associated with the disease are pregnancy, sexual hormones, sun exposure, sue of cosmetics, photosensitizing drugs, steroids and inflammatory process of the skin. Patients generally feels lack of motivation to go out, anhedonia, low-self-esteem, dissatisfaction and feeling of shame. The University of Pittsburgh is in the process of developing TCA peel for the treatment of melisma. Allergan, Inc. is in the process of developing hydroquinone topical cream for the treatment of melisma. Some of the companies and universities having the pipeline of melisma include Allergan, Inc., Assiut University, University of Pittsburgh, and others.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/melasma-therapeutics-pipeline-analysis/report-sample
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Explore Report at: https://www.psmarketresearch.com/market-analysis/melasma-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Prostatitis Therapeutics Pipeline - Pipeline Analysis 2017, Clinical Trials & Results, Patent and Developments
The study analyzed that the Prostatitis therapeutics pipeline comprises 11 drug candidates in different stages of development. Prostatitis is an infection or inflammation of the prostate gland that can lead to various syndromes with varying clinical features. The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The National Institutes of Health (NIH) has recognized and defined a classification system for prostatitis in 1999.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/prostatitis-therapeutics-pipeline/report-sample
The drug candidates of prostatitis pipeline are in different stages of development. Among them, majority of drugs are being developed to be administered by oral route. For instance, Prulifloxacin, a Phase II drug candidate by Angelini Acraf SpA, is being developed to be administered by oral route. Oral route increases the patient compliance as it does not require the assistance of other healthcare professionals. It is the prodrug of ulifloxacin a broad-spectrum fluoroquinolone antibacterial agent that blocks the type II DNA topoisomerase.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=prostatitis-therapeutics-pipeline
Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.
Myelofibrosis Therapeutics - Clinical Trials & Results, Patent and Developments
Myelofibrosis currently exhibits a pipeline of 29 drug candidates. The study analysed that the therapeutics pipeline comprises of approximately 29 drug candidates in different stages of development. Myelofibrosis is a rare disorder in which excessive scar tissue gets formed in the bone marrow that impairs its ability to produce red blood cells. However, it is believed by researchers that myelofibrosis occurs due to the presence of abnormal red blood stem cells in the bone marrow. The abnormal blood stem cells produce mature cells that grow quickly and form scar tissue which leads to chronic inflammation.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis/report-sample
Various companies, educational institutes and medical organization are collaborating for the development of therapeutics for the treatment of myelofibrosis. For instance, Geron Corporation and Janssen Pharmaceuticals, Inc. entered into a collaboration agreement, in which Geron Corporation granted an exclusive worldwide right to Janssen, for the development and commercialization of imetelstat for all human therapeutic uses, including hematologic myeloid malignancies.
According to the research, there are several companies having drug candidates in their pipeline, using synthetic sources for the development of drugs for the treatment of myelofibrosis. Imetelstat is an oligonucleotide obtained from synthetic source that acts as telomerase inhibitor.
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=myelofibrosis-therapeutics-pipeline-analysis
Some of the key players developing drugs for myelofibrosis include CTI BioPharma Corporation, Geron Corporation, Gilead Sciences, Inc. and others.
Antibody Drug Conjugates Therapeutics Market - Pipeline Analysis, Size and Growth, 2023
The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/report-sample
The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.
ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/adcs-therapeutics-market/toc-sample
Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.
